TMBIM4 and COVID-19: Although S1R is foregrounded in COVID-19 research, it is currently unclear if a S1R antagonist or agonist could be better to treat the disease, since in vitro reports show that S1R antagonists prevent SARS-CoV-2 replication and S1R agonists have proviral activity, while clinical evidence suggests that S1R agonists prevent worsening of symptoms.